IRIS
PALAZZUOLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.105
EU - Europa 4.870
AS - Asia 3.396
SA - Sud America 604
Continente sconosciuto - Info sul continente non disponibili 223
AF - Africa 138
OC - Oceania 11
Totale 18.347
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.994
RU - Federazione Russa 1.191
CN - Cina 1.096
SG - Singapore 963
GB - Regno Unito 932
IT - Italia 771
IE - Irlanda 555
BR - Brasile 483
VN - Vietnam 437
SE - Svezia 310
HK - Hong Kong 288
UA - Ucraina 278
DE - Germania 251
FR - Francia 226
BD - Bangladesh 171
FI - Finlandia 166
KR - Corea 144
IN - India 95
ZA - Sudafrica 61
AR - Argentina 54
CA - Canada 45
MX - Messico 40
TR - Turchia 35
IQ - Iraq 29
NL - Olanda 29
ES - Italia 28
BE - Belgio 23
PL - Polonia 23
JP - Giappone 22
CZ - Repubblica Ceca 20
KE - Kenya 19
EC - Ecuador 14
PK - Pakistan 14
CO - Colombia 13
UZ - Uzbekistan 13
CL - Cile 12
NG - Nigeria 12
SA - Arabia Saudita 12
ID - Indonesia 11
MA - Marocco 11
PE - Perù 11
AU - Australia 9
NP - Nepal 9
PY - Paraguay 9
CI - Costa d'Avorio 8
GR - Grecia 7
IL - Israele 7
AT - Austria 6
BG - Bulgaria 6
DK - Danimarca 6
EG - Egitto 6
LT - Lituania 6
MY - Malesia 6
VE - Venezuela 6
AL - Albania 5
AZ - Azerbaigian 5
CR - Costa Rica 5
DZ - Algeria 5
JM - Giamaica 5
PH - Filippine 5
PT - Portogallo 5
RO - Romania 5
IR - Iran 4
JO - Giordania 4
PS - Palestinian Territory 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
PA - Panama 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
CH - Svizzera 2
IM - Isola di Man 2
KH - Cambogia 2
LV - Lettonia 2
LY - Libia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
RS - Serbia 2
SC - Seychelles 2
SI - Slovenia 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
DM - Dominica 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
Totale 18.115
Salva come PNG Salva come JPEG
Città #
Dallas 3.339
Southend 746
Ashburn 572
Singapore 554
Dublin 549
Fairfield 535
Moscow 369
San Jose 313
Chandler 311
Woodbridge 278
Beijing 272
Hong Kong 272
Santa Clara 272
Ann Arbor 264
Milan 258
Houston 238
Council Bluffs 231
Jacksonville 221
Seattle 219
Wilmington 214
Hefei 209
Cambridge 172
Seoul 141
Los Angeles 124
Dong Ket 117
New York 112
Rome 103
The Dalles 99
Princeton 92
Ho Chi Minh City 90
Hanoi 86
Munich 80
Nanjing 77
Siena 77
Lauterbourg 70
Helsinki 65
Johannesburg 58
Columbus 55
Buffalo 54
Shanghai 49
Turku 49
São Paulo 48
Dearborn 44
Boardman 43
Changchun 41
San Nicola la Strada 37
Orem 33
London 31
Phoenix 31
Denver 28
San Mateo 25
Bengaluru 24
Brussels 23
Frankfurt am Main 23
Chicago 22
Rio de Janeiro 22
Shenyang 21
Lancaster 20
Düsseldorf 19
Florence 19
Redondo Beach 19
Tokyo 19
Warsaw 18
Brooklyn 17
Chennai 17
Haiphong 17
Naples 17
Atlanta 16
Jiaxing 16
Kunming 16
Nanchang 16
San Diego 16
Toronto 16
Changsha 15
Da Nang 15
Hebei 15
Mexico City 15
Tianjin 14
Turin 14
Baghdad 13
Jinan 13
Manchester 13
Montreal 12
San Francisco 12
Tashkent 12
Washington 12
Belo Horizonte 11
Biên Hòa 11
Figino 11
Mumbai 11
Nairobi 11
Amsterdam 10
Brno 10
Guangzhou 10
Menlo Park 10
Portsmouth 10
Abuja 9
Barnet 9
Boston 9
Izmir 9
Totale 13.096
Salva come PNG Salva come JPEG
Nome #
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 1.018
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 803
The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines 448
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. 415
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 395
B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. 379
Sex-related differences in chronic heart failure 346
B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function 345
Natriuretic peptides in heart failure: where we are, where we are going. 319
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure 307
H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease 307
Myocardial 123I-metaiodobenzylguanidine imaging in hypertension and left ventricular hypertrophy 306
Quantitative evaluation of microvessels in Behcet's disease 295
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia 292
Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance 292
Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. 288
Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide 283
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction 280
Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure 268
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 267
Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure 265
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 264
Prognostic significance of hyperuricemia in patients with acute heart failure 262
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial 260
The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions 245
Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy 240
Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management 236
The role of fibrosis and inflammation for response and outcome prediction in candidates to cardiac resynchronization therapy: is response the right answer? 234
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure 231
Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function 229
Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application 228
Definizione di pattern videocapillaroscopici (VCS) di normalità nel microcircolo cutaneo. Stratificazione secondo l'età 226
Dyslipidemias and fibrinolysis. 214
Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization 213
The role of natriuretic peptides for the diagnosis of left ventricular dysfunction 209
Natriuretic peptides and NGAL in heart failure: does a link exist? 209
Current therapeutic strategies in cardiorenal syndrome 200
Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection 197
Peptide natriuretico di tipo B ed ecocardiografia Doppler nella diagnosi di scompenso cardiaco: Metodiche alternative o complementari? [B-type natriuretic peptide and Doppler echocardiography in the diagnosis of heart failure: alternative or complementary tools?] 196
Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension 193
Heart failure: pathophysiology and clinical picture. 192
The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study 191
From gene mutations to biomechanical abnormalities and electrophysiological remodeling in hypertrophic cardiomyopathy: exploring the translational approach. 185
The potential role of natriuretic peptides in acute coronary syndrome stratification 175
A multidisciplinary approach in neurofibromatosis 1 174
Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? 171
Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes 168
Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients 164
Arterial hypertension and atrial fibrillation: Standard and advanced echocardiography from diagnosis to prognostication 162
Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries 160
Pulmonary congestion assessment in heart failure: traditional and new tools 154
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure 144
Clinical impact of oral antidiabetic medications in heart failure patients 144
Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection 142
The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure 132
Chronotropic incompetence across heart failure categories 129
The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is “response” the right answer? 125
null 122
null 120
Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF 119
Usefulness of combined ultrasound assessment of E/e' ratio, pulmonary pressure, and cava vein status in patients with acute heart failure 118
Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure 116
Additional value of Galectin-3 respect to BNP in acute heart failure patients with preserved ejection fraction 115
Clinical impact of renal dysfunction in heart failure 114
Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care 113
null 111
The predictive value of plasma biomarkers in discharged heart failure patients: the role of plasma BNP 110
Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. 108
Effects of metolazone administration on congestion, diuretic response and renal function in patients with advanced heart failure 107
null 105
Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence 102
null 100
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy 98
Cardio-renal syndrome revealed increased neurohormonal activity, tubular and myocardial damage respect to heart failure patients with preserved renal function 97
Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction 97
Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF 97
Combination Between Biomarkers and Echocardiographic Data for Prediction of Left Ventricular Reverse Remodelling in Cardiac Resynchronization Therapy 95
Integrated Cardiorespiratory Rehabilitation and Its Impact on Cardio-Renal-Metabolic Profile After Cardiac Surgery 93
Right ventricular dysfunction in chronic heart failure: Clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry) 88
Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update 87
Heart failure outpatient clinics resources in Italy: a viewpoint of Italian Society of Cardiology organization 86
The relevance of specific heart failure outpatient programs in the COVID era: An appropriate model for every disease 82
Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature 79
The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction 77
Continuous versus intermittent loop diuretics infusion dosing in acute heart failure: effects on renal function, outcome and BNP levels 75
The assessment, interpretation and implementation of lung ultrasound examinations in Heart Failure: Current evidence and gaps in knowledge 66
Different neurohormonal and inflammatory pattern in acute CRS respect to AHF patients with preserved renal function 65
Contemporary assessment of lung ultrasound, BNP and echocardiography for outcome prediction in patients with decompensated heart failure 64
Resistant hypertension: An overview 62
The Role of Lung Ultrasound Scan in Different Heart Failure Scenarios: Current Applications and Lacks of Evidences 59
Contemporary assessment of lung ultrasound, bnp and echocardiography predicts outcome in patients with acute heart failure independently to systolic dysfunction 58
Transient versus persistent worsening renal function during hospitalization in acute heart failure: different phenotypes for different outcome 46
Dynamic variation of renal function and novel or old HF biomarkers (ST2, Galectin 3, NT-proBNP) and response to cardiac resynchronization therapy (CRT) 43
Multi-biomarkers laboratory strategy for outcome prediction in patients with severe systolic dysfunction submitted to CRT 40
Plasma Neuthrophil Gelatinase associated Lipocalin (NGAL) predict worsening renal function and outcome in patients with acute decompensated heart failure 32
Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated 27
Continuous versus intermittent loop diuretics step‐by‐step protocol in acute heart failure (DIUR‐AHF): a propensity‐matched analysis 11
Incidental cardiac mass: Differential diagnosis, clinical approach and review of the literature,Massa cardiaca incidentale: Diagnosi differenziale, approccio clinico e revisione della letteratura 11
Continuous vs intermittent loop diuretics in acute Heart Failure (DIUR-AHF): a propensity matched analysis 9
Impact of Dapaglizofin on right ventricular function and pulmonary pressure: a secondary analysis of the RIVED registry 7
Totale 18.347
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.920
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022614 0 70 31 70 60 24 28 24 38 72 65 132
2022/20231.016 61 90 136 131 112 189 24 80 86 18 32 57
2023/2024873 46 21 96 41 19 224 303 21 5 23 12 62
2024/20252.142 41 70 136 106 232 166 113 104 168 101 270 635
2025/20269.044 481 1.666 2.226 899 1.239 249 654 157 201 431 305 536
2026/2027459 292 167 0 0 0 0 0 0 0 0 0 0
Totale 18.347